SCHEMBL21982521

SCHEMBL21982521

COCCC(C)c1ncc2c(n1)NC1(CCNCC1)C(NCc1cccc(Cl)c1)=N2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNT1 O60563 1/20 0.37
▸ HTR6 P50406 3/20 0.34
▸ MAOB P27338 2/20 0.34
▸ ACAT2 Q9BWD1 1/20 0.34
▸ PDE2A O00408 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ CDK9 P50750 1/20 0.33
▸ PDE9A O76083 2/20 0.33
▸ TMIGD3 P0DMS9 1/20 0.33
▸ HTR2C P28335 1/20 0.33
▸ HTR2B P41595 1/20 0.33
▸ HDAC3 O15379 1/20 0.32
▸ HDAC1 Q13547 1/20 0.32
▸ HDAC2 Q92769 1/20 0.32
▸ HDAC6 Q9UBN7 1/20 0.32
▸ IDH1 O75874 1/20 0.32
▸ FYN P06241 2/20 0.32
▸ GAA P10253 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ RXFP1 Q9HBX9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17758126 0.84 CCNT1 (0.38) CCNT1HTR6MAOBACAT2TMIGD3
SCHEMBL17758134 0.78 CCNT1 (0.39) CCNT1HTR6MAOBACAT2CDK9
SCHEMBL17758132 0.77 HRH4 (0.39) CCNT1HTR6MAOBPDE2ACDK9
SCHEMBL21982507 0.77 CCNT1 (0.37) CCNT1PDE2ACDK9TMIGD3HTR2C
SCHEMBL17757779 0.77 ACAT2 (0.37) CCNT1HTR6MAOBACAT2CDK9
SCHEMBL17757306 0.77 ACAT2 (0.41) CCNT1HTR6MAOBACAT2CDK9
SCHEMBL17757259 0.76 HDAC3 (0.40) CCNT1HTR6MAOBACAT2HDAC3
SCHEMBL17758026 0.76 ACAT2 (0.41) CCNT1HTR6MAOBACAT2CDK9
SCHEMBL17757793 0.76 ACAT2 (0.41) CCNT1HTR6MAOBACAT2RXFP1
SCHEMBL17757775 0.75 EIF2AK1 (0.41) CCNT1HTR6MAOBACAT2FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) 2020-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death AIFM2, BAD, AIFM1 CCNT1 4252/4885HTR6 1352/4885MAOB 2633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback